Stem Cell Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Stem Cell Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Graft-versus-Host Disease
RDP58 does not prevent graft-versus-host disease
August 14th, 2006
RDP58, a peptide derived from the human leukocyte antigen class I heavy chain, does not prevent graft-versus-host disease after leukocyte antigen-nonidentical hematopoietic cell transplantation. According to recent research from the United States, "Graft-versus-host disease (GVHD) remains a cause of substantial morbidity for patients undergoing allogeneic hematopoietic cell transplantation (HCT). "The present study was undertaken to investigate the effectiveness of RDP58, a peptide derived from the human leukocyte antigen class I heavy chain, in preventing GVHD in the established dog leukocyte antigen (DLA)-nonidentical canine model." ...
Source: Stem Cell Week (2006-08-14)
|
